Form 4: Whitehawk CMO Receives Significant Equity Grant

Whitehawk Therapeutics' Chief Medical Officer, Margaret Dugan, was granted 650,000 stock options and 55,309 Restricted Stock Units, aligning her incentives with shareholder value.

Summary

• Margaret Dugan, Chief Medical Officer of Whitehawk Therapeutics, Inc. (WHWK), reported the acquisition of derivative securities.
• The transaction, dated December 1, 2025, involved the grant of 650,000 stock options.
• These stock options have an exercise price of $2.26 per share and an expiration date of December 1, 2035.
• Additionally, 55,309 Restricted Stock Units (RSUs) were granted.
• The Vesting Commencement Date for both the stock options and RSUs is December 1, 2025.
• The stock options vest 25% on the one-year anniversary of the Vesting Commencement Date, and then 1/48th of the total shares subject to the option vest each month thereafter, leading to full vesting on the four-year anniversary.
• The Restricted Stock Units (RSUs) vest 100% on the one-year anniversary of the Vesting Commencement Date.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally positive as it aligns management's interests with long-term shareholder value and serves as a retention mechanism. The potential for future dilution is a minor consideration against the positive alignment.

Positives

• The equity grants align the Chief Medical Officer's interests with long-term shareholder value, incentivizing performance.
• The awards serve as a retention mechanism for key executive talent, ensuring continuity in leadership.
• The multi-year vesting schedules encourage continued service and commitment to the company's strategic objectives.

Negatives

• The future exercise of stock options and vesting of RSUs could lead to potential dilution for existing shareholders.

Risks

• The ultimate value realized from these equity awards is contingent on the future market price of Whitehawk Therapeutics, Inc. common stock.
• Vesting of both stock options and RSUs is subject to the reporting person continuing to be a Service Provider, meaning forfeiture if employment ceases before vesting conditions are met.

Future Outlook

The structured vesting schedules for the equity awards indicate an expectation of continued service from the Chief Medical Officer for at least one to four years, aligning her incentives with the company's long-term success and strategic goals.

Industry Context

Granting equity awards such as stock options and Restricted Stock Units is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives, aligning their compensation with company performance and shareholder interests.

Comparison to Industry Standards

• These types of equity grants, with multi-year vesting schedules, are standard compensation tools across publicly traded companies, particularly in growth-oriented sectors like biotech.
• The structure of the awards (options and RSUs) and their vesting terms are consistent with typical executive compensation packages designed to foster long-term commitment and performance, although specific comparable companies or projects are not detailed in the filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options and vesting of RSUs, but also improved alignment of executive incentives with long-term company performance.
• Employees: May signal confidence in the company's future and provide a benchmark for executive compensation practices.

Next Steps

• The Chief Medical Officer must continue her service to Whitehawk Therapeutics, Inc. to fulfill the vesting conditions and realize the value of the equity awards.

Key Dates

Keywords

Whitehawk Therapeutics, WHWK, Form 4, SEC filing, stock options, Restricted Stock Units, RSU, equity compensation, executive compensation, insider transaction, Chief Medical Officer, Margaret Dugan